Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach

摘要: Objective Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have described in patients with gynecological oligometastatic cancer, particularly ovarian neoplasm. The aim this study was evaluate the role new radiotherapy modality a series cancer patients. Materials and Methods Clinical records affected by carcinoma treated SBRT were reviewed. Results Twenty-six 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; lung, 4.5%) between January 2011 May 2017 analyzed. After median follow-up period 28.5 months (range, 6–86 months), 17 (65.4%) still alive at time analysis: 6 are without evidence disease, 11 experienced disease progression. Eight died 1 because an heart attack while being free. local control (LC) not reached. One-, 2-, 5-year LCs 92.9%. Median progression-free survival 19 months, 1-year 69.3% 38% 2 years, 19% 5 years. overall 64.5 all after year, 92.7% 61.7% Five (11.3%) cases G2 toxicity; most common adverse effect nausea vomiting (3 [6.8%]) followed abdominal pain (2 [4.5%]). None had grade 3 or 4 acute late toxicity. Conclusions In conclusion, is feasible safe approach for selected satisfactory results terms LC free survival.